Influence of chemotherapy on reproductive system: methods of protection and preservation of ovarian function

The recent studies showed the great importance of discussing the issue of protection and preservation of the ovarian function in cancer patients. Nowadays, when new effective methods of treatment are available, many cancer patients wish to realize their reproductive function. In this review, we discuss the methods of ovarian protection such as pharmacological protection and IVF program including a cryopreservation and transplantation of ovarian tissue or cryopreservation of oocytes and embryos.

• M.V. Volochayeva V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, RF Ministry of Health, Moscow, Russian Federation ; ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. В.И. Кулакова» МЗ РФ, Москва, Российская Федерация
• R.G. Shmakov V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, RF Ministry of Health, Moscow, Russian Federation ; ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. В.И. Кулакова» МЗ РФ, Москва, Российская Федерация
• Ye.A. Demina N.N. Blokhin Russian Cancer Research Centre, RAMS, Moscow, Russian Federation ; ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва, Российская Федерация

1. Демина Е.А., Махова Е.Е., Сусулева Н.А., Ильященко В.А. Возможности сохранения детородной функции у женщин с лимфомой Ходжкина. РМЖ 2005; 1: 26–8.[Demina Ye.A., Makhova Ye.Ye., Susuleva N.A., and Ilyashchenko V.A. Potentials for preservation of reproductive function in females with Hodgkin’s lymphoma. RMZh 2005: 1:26–8. (In Russ.)].
2. Шмаков Р.Г. Репродуктивное здоровье женщин с онкогематологическими заболеваниями: Автореф. дис. … д-ра мед. наук. М., 2008.[Shmakov R.G. Reproduktivnoye zdorove zhenshchin s onkogematologicheskimi zabolevaniyami. Dokt. diss. (Reproductive health in women with hematological malignancies : Dr. med. sci. diss.). M., 2008.]
3. Maltaris T., Seufert R., Fischl F. et al. The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007; 130: 148–55. DOI: https://doi.org/10.1016/j.ejogrb.2006.08.006
4. Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J. Soc. Gynecol. Investig. 2001; 8: 60–4. DOI: https://doi.org/10.1177/1071557601008001S19
5. Blumenfeld Z. Reservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol. Cell. Endocrinol. 2002; 187: 93–105. DOI: https://doi.org/10.1016/S0303-7207(01)00712-2
6. Minton S.E., Munster P.N. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002; 9: 466–72. DOI: https://doi.org/10.1177/107327480200900603
7. Mrozek E., Shapiro C.L. Survivorship and complications of treatment in breast cancer. Clin. Adv. Hematol. Oncol. 2005; 3: 211–22.
8. Friedman D.L., Constine L.S. Late effects of treatment for Hodgkin lymphoma. J. Natl. Compr. Cancer Network 2006; 4: 249–57. DOI: https://doi.org/10.6004/jnccn.2006.0024
9. Haukvik U.K., Dieset I., Bjoro T. et al. Treatment-related premature ovarian failure as a long-term complication after Hodgkin’s lymphoma. Ann. Oncol. 2006; 17: 1428–33. DOI: https://doi.org/10.1093/annonc/mdl149
10. Behringer K., Mueller H., Goergen H. et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J. Clin. Oncol. 2013; 31: 231–9. DOI: https://doi.org/10.1200/JCO.2012.44.3721
11. De Bruin M.L., Huisbrink J., Hauptmann M. et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008; 111: 101–8. DOI: https://doi.org/10.1182/blood-2007-05-090225
12. Van der Kaaij M.A., van Echten-Arends J., Simons A.H. et al. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol. Oncol. 2010; 28: 168–79. DOI: https://doi.org/10.1002/hon.939
13. Fornier M.N., Modi S., Panageas K.S. et al. Incidence of chemotherapy induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005; 104: 1575–9. DOI: https://doi.org/10.1002/cncr.21385
14. Behringer K., Breuer K., Reineke T. et al. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J. Clin. Oncol. 2005; 23: 7555–64. DOI: https://doi.org/10.1200/JCO.2005.08.138
15. Gerber B., Dieterich M., Muеller H. et al. Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Res. Treat. 2008; 108: 1–7. DOI: https://doi.org/10.1007/s10549-007-9572-1
16. Okanami Y., Ito Y., Watanabe C. et al. Incidence of chemotherapy induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer 2011; 18: 182–8. DOI: https://doi.org/10.1007/s12282-011-0256-7
17. Lee S.J., Schover L.R., Partridge A.H. et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 2006; 24: 2917–31. DOI: https://doi.org/10.1200/JCO.2006.06.5888
18. Tham Y.L., Sexton K., Weiss H. et al. The rates of chemotherapy induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am. J. Clin. Oncol. 2007; 30: 126–32. DOI: https://doi.org/10.1097/01.coc.0000251398.57630.4f
19. Sklar C.A., Mertens A.C., Mitby P. et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J. Natl. Cancer Inst. 2006; 98: 890–6. DOI: https://doi.org/10.1093/jnci/djj243
20. Dillon K.E., Sammel M.D., Prewitt M. et al. Pretreatment antimullerian hormone levels determine rate of post therapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil. Steril. 2013; 99: 477–83. DOI: https://doi.org/10.1016/j.fertnstert.2012.09.039
21. Wallace W.H., Thomson A.B., Saran F. et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int. J. Radiat. Oncol. Biol. Phys. 2005; 62: 738–44. DOI: https://doi.org/10.1016/j.ijrobp.2004.11.038
22. Knauff E.A., Eijkemans M.J., Lambalk C.B. et al. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J. Clin. Endocrinol. Metab. 2009; 94: 786–92. DOI: https://doi.org/10.1210/jc.2008-1818
23. Iwase A., Sugita A., Hirokawa W. et al. Anti-Mullerian hormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013; 167: 194–8. DOI: https://doi.org/10.1016/j.ejogrb.2012.11.021
24. Munster P.N., Moore A.P., Ismail-Khan R. et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 2012; 30: 533–8. DOI: https://doi.org/10.1200/JCO.2011.34.6890
25. Recchia F., Saggio G., Amiconi G. et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006; 106: 514–23. DOI: https://doi.org/10.1002/cncr.21646
26. Han S.S., Kim Y.H., Lee S.H. et al. Underuse of ovarian transposition in reproductive-aged cancer patients treated by primary or adjuvant pelvic irradiation. J. Obstet. Gynaecol. Res. 2011; 37: 825–9. DOI: https://doi.org/10.1111/j.1447-0756.2010.01443.x
27. Pentheroudakis G., Pavlidis N., Castiglione M. Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009; 20: 178–81 (Suppl. 4). DOI: https://doi.org/10.1093/annonc/mdp166
28. Donnez J., Dolmans M.M. Cryopreservation and transplantation of ovarian tissue. Clin. Obstet. Gynecol. 2010; 53: 787–96. DOI: https://doi.org/10.1097/GRF.0b013e3181f97a55
29. Bedaiwy M.A., Abou-Setta A.M., Desai N. et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: A systematic review and meta-analysis. Fertil. Steril. 2011; 95: 906–14, e1–4. DOI: https://doi.org/10.1016/j.fertnstert.2010.11.017
30. Blumenfeld Z., von Wolff M. GnRH analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum. Reprod. Update 2008; 14: 543–52. DOI: https://doi.org/10.1093/humupd/dmn022
31. Демина Е.А., Перилова Е.Е., Шмаков Р.Г. Использование комбинированных пероральных контрацептивов для профилактики повреждения функции яичников у больных лимфомой Ходжкина. М., 2004: 1352–4. [Demina Ye.A., Perilova Ye.Ye., Shmakov R.G. Ispolzovaniye kombinirovannykh peroralnykh kontratseptivov dlya profilaktiki povrezhdeniya funktsii yaichnikov u bolnykh limfomoy Khodzhkina (Use of oral contraceptives for prevention of ovarian function damage in patients with Hodgkin’s lymphoma). M., 2004: 1352–4.]
32. Blumenfeld Z., Avivi I., Linn S. et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum. Reprod. 1996; 11: 1620–6. DOI: https://doi.org/10.1093/oxfordjournals.humrep.a019457
33. Badawy A., Elnashar A., El-Ashry M. et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil. Steril. 2009; 91: 694–7. DOI: https://doi.org/10.1016/j.fertnstert.2007.12.044
34. Sverrisdottir A., Nystedt M., Johansson H. et al. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res. Treat. 2009; 117: 561–7. DOI: https://doi.org/10.1007/s10549-009-0313-5
35. Clowse M.E., Behera M.A., Anders C.K. et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J. Womens Health 2009; 18: 311–9. DOI: https://doi.org/10.1089/jwh.2008.0857
36. Del Mastro L., Boni L., Michelotti A. et al. Effect of the gonadotropinreleasing hormone analogue triptorelin on the occurrence of chemotherapyinduced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011; 306: 269–76. DOI: https://doi.org/10.1001/jama.2011.991
37. Chen H., Li J., Cui T. et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011; 9: CD008018. DOI: https://doi.org/10.1002/14651858.CD008018.pub2
38. Wong M., O’Neill S., Walsh G. et al. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann. Oncol. 2013; 24: 133–8. DOI: https://doi.org/10.1093/annonc/mds250
39. Yang B., Shi W., Yang J. et al. Concurrent treatment with gonadotropinreleasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: A meta-analysis of randomized controlled trials. Breast 2013; 22: 150–7. DOI: https://doi.org/10.1016/j.breast.2012.12.008
40. Leonard R.C., Adamson D., Anderson R. et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J. Clin. Oncol. 2010; 28: Abstract 590. DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.590
41. Gerber B., von Minckwitz G., Stehle H. et al. Effect of luteinizing hormonereleasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J. Clin. Oncol. 2011; 29: 2334–41. DOI: https://doi.org/10.1200/JCO.2010.32.5704
42. Elgindy E.A., El-Haieg D.O., Khorshid O.M. et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet. Gynecol. 2013; 121: 78–86. DOI: https://doi.org/10.1097/AOG.0b013e31827374e2
43. American Society for Reproductive Medicine. http://www.asrm.org
44. Azim A.A., Costantini-Ferrando M., Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: A prospective controlled study. J. Clin. Oncol. 2008; 26: 2630–5. DOI: https://doi.org/10.1200/JCO.2007.14.8700
45. Oktay K., Buyuk E., Libertella N. et al. Fertility preservation in breast cancer patients: A prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J. Clin. Oncol. 2005; 23: 4347–53. DOI: https://doi.org/10.1200/JCO.2005.05.037
46. Lee S., Oktay K. Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer? Fertil. Steril. 2012; 98: 961.e1–4.e1. DOI: https://doi.org/10.1016/j.fertnstert.2012.06.015
47. Sonmezer M., Turkcuoglu I., Coskun U., Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil. Steril. 2011; 95: 2125.e9–11. DOI: https://doi.org/10.1016/j.fertnstert.2011.01.030
48. Isachenko V., Isachenko E., Keck G. et al. First live birth in Germany after re-transplantation of cryopreserved ovarian tissue: Original device for initiation of ice formation. Clin. Lab. 2012; 58: 933–8.
49. Bacigalupo A., Ballen K., Rizzo D. et al. Defining the intensity of conditioning regimens: Working definitions. Biol. Blood Marrow Transplant. 2009; 15: 1628–33. DOI: https://doi.org/10.1016/j.bbmt.2009.07.004
50. Borini A., Bianchi V. Cryopreservation of mature and immature oocytes. Clin. Obstet. Gynecol. 2010; 53: 763–74. DOI: https://doi.org/10.1097/GRF.0b013e3181f96f01
51. Huang J.Y., Chian R.C., Gilbert L. et al. Retrieval of immature oocytes from unstimulated ovaries followed by in vitro maturation and vitrification: A novel strategy of fertility preservation for breast cancer patients. Am. J. Surg. 2010; 200: 177–83. DOI: https://doi.org/10.1016/j.amjsurg.2009.04.004
52. Rudick B., Opper N., Paulson R. et al. The status of oocyte cryopreservation in the United States. Fertil. Steril. 2010; 94: 2642–6. DOI: https://doi.org/10.1016/j.fertnstert.2010.04.079
53. Demeestere I., Simon P., Emiliani S., Delbaere A., Englert Y. Orthotopic and heterotopic ovarian tissue transplantation. Hum. Reprod. Update 2009; 15: 649–65. DOI: https://doi.org/10.1093/humupd/dmp021
54. Demeestere I., Moffa F., Peccatori F., Poirot C., Shalom-Paz E. Multiple approaches for individualized fertility protective therapy in cancer patients. Obstet. Gynecol. Int. 2012: 495142 (Medline Abstract). DOI: https://doi.org/10.1155/2012/961232
55. Oktay K., Cil A.P., Bang H. Efficiency of oocyte cryopreservation: A metaanalysis. Fertil. Steril. 2006; 86: 70–80. DOI: https://doi.org/10.1016/j.fertnstert.2006.03.017
56. Donnez J., Squifflet J., Jadoul P. et al. Pregnancy and live birth after autotransplantation of frozen-thawed ovarian tissue in a patient with metastatic disease undergoing chemotherapy and hematopoietic stem cell transplantation. Fertil. Steril. 2011; 95: 1787.e1–4. DOI: https://doi.org/10.1016/j.fertnstert.2010.11.041
57. Kim M.K., Lee D.R., Han J.E. et al. Live birth with vitrified-warmed oocytes of a chronic myeloid leukemia patient nine years after allogenic bone marrow transplantation. J. Assist. Reprod. Genet. 2011; 28: 1167–70. DOI: https://doi.org/10.1007/s10815-011-9681-y
58. Dittrich R., Lotz L., Keck G. et al. Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation. Fertil. Steril. 2012; 97: 387–90. DOI: https://doi.org/10.1016/j.fertnstert.2011.11.047
59. Andersen C.Y., Silber S.J., Berghold S.H. et al. Long-term duration of function of ovarian tissue transplants: Case reports. Reprod. Biomed. Online 2012; 25: 128–32. DOI: https://doi.org/10.1016/j.rbmo.2012.03.014
60. Oktay K., Rodriguez-Wallberg K.A. Four spontaneous pregnancies and three live births following subcutaneous transplantation of frozen banked ovarian tissue: What is the explanation? Fertil. Steril. 2011; 95: 804.e7–10. DOI: https://doi.org/10.1016/j.fertnstert.2010.07.1072
61. Meirow D., Levron J., Eldar-Geva T. et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N. Engl. J. Med. 2005; 353: 318–21. DOI: https://doi.org/10.1056/NEJMc055237
62. Anderson R.A., Wallace W.H., Baird D.T. Ovarian cryopreservation for fertility preservation: Indications and outcomes. Reproduction 2008; 136: 681–9. DOI: https://doi.org/10.1530/REP-08-0097
63. Reebals J.F., Brown R., Buckner E.B. Nurse practice issues regarding sperm banking in adolescent male cancer patients. J. Pediatr. Oncol. Nurs. 2006; 23: 182–8. DOI: https://doi.org/10.1177/1043454206289868
64. Keros V., Hultenby K., Borgstrumlom B. et al. Methods of cryopreservation of testicular tissue with viable spermatogonia in pre-pubertal boys undergoing gonadotoxic cancer treatment. Hum. Reprod. 2007; 22: 1384–95. DOI: https://doi.org/10.1093/humrep/del508
65. Jadoul P., Dolmans M.M., Donnez J. Fertility preservation in girls during childhood: Is it feasible, efficient and safe and to whom should it be proposed? Hum. Reprod. Update 2010; 16: 617–30. DOI: https://doi.org/10.1093/humupd/dmq010
66. Cvancarova M., Samuelsen S.O., Magelssen H. et al. Reproduction rates after cancer treatment: Experience from the Norwegian radium hospital. J. Clin. Oncol. 2009; 27: 334–43. DOI: https://doi.org/10.1200/JCO.2007.15.3130
67. Nieman C.L., Kinahan K.E., Yount S.E. et al. Fertility preservation and adolescent cancer patients: Lessons from adult survivors of childhood cancer and their parents. Cancer Treat. Res. 2007; 138: 201–17 DOI: https://doi.org/10.1007/978-0-387-72293-1_15